Table 2 Summary of practical aspects of guidelines
From: Contrast-induced nephropathy: pharmacology, pathophysiology and prevention
| Â | ESUR | ACR |
|---|---|---|
Indications for SC measurement prior to contrast medium administration | - Age >70 - History of: renal disease, renal cancer, proteinuria, diabetes mellitus, hypertension, gout, recent nephrotoxic drugs - Known eGFR <60 - Intra-arterial contrast medium administration | - Age >60 - History of: renal disease, renal cancer, renal surgery, kidney transplant, single kidney, dialysis, hypertension requiring medical therapy, diabetes mellitus - Use of metformin |
Interval SC measurement – contrast medium administration | Within 7 days | No universally accepted interval |
Volume expansion with NaCl 0.9 % i.v. | 1-1.5 ml/kg/h ≥6 h before, ≥6 h after contrast medium administration | 100 ml/h 6–12 h before, 4–12 h after CM administration |
Volume expansion with NaHCO3 1.4Â % | 3Â ml/kg/h 1Â h before, 1Â ml/kg/h 6Â h after contrast medium administration | No definite results |
Emergency volume expansion | Start as early as possible | No guidelines |
Post contrast medium administration SC measurement | Determine eGFR 48–72 h post contrast medium administration in high risk patients | No guidelines |
Nephrotoxic drugs | Cyclosporin Cisplatin Aminoglycosides NSAID | No guidelines |